Medikamentöse Therapie des fortgeschrittenen Blasenkarzinoms: Neue Entwicklungen 2014

S. C. Schmid; J. E. Gschwend; M. Retz

doi:10.1007/s00120-014-3641-y

Medikamentöse Therapie des fortgeschrittenen Blasenkarzinoms: Neue Entwicklungen 2014

Translated title of the contribution: Pharmaceutical treatment of advanced urinary bladder cancer: New developments in 2014

S. C. Schmid
, J. E. Gschwend
, M. Retz

Technical University of Munich

Research output: Contribution to journal › Article › peer-review

Abstract

The perioperative treatment of muscle-invasive bladder cancer has become a standard procedure in recent years. New agents, such as programmed cell death protein 1 (PD1) and PD1-ligand 1 (PD1-L1) inhibitors have opened up the door for immunomodulation therapy of metastasized bladder cancer. This article focuses on data which have changed or have the potential to change the pharmaceutical treatment of advanced bladder cancer with a review of the literature in Medline PubMed and proceedings of major meetings, e.g. the European Association of Urology (EAU), the American Society of Clinical Oncology (ASCO), the ASCO Genitourinary Cancers Symposium (ASCO GU) and the American Urological Association (AUA).

Translated title of the contribution	Pharmaceutical treatment of advanced urinary bladder cancer: New developments in 2014
Original language	German
Pages (from-to)	1535-1542
Number of pages	8
Journal	Urologe - Ausgabe A
Volume	53
Issue number	10
DOIs	https://doi.org/10.1007/s00120-014-3641-y
State	Published - 8 Oct 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1007/s00120-014-3641-y

Cite this

@article{2997610374cf4597b5f8a81ba00e7007,

title = "Medikament{\"o}se Therapie des fortgeschrittenen Blasenkarzinoms: Neue Entwicklungen 2014",

abstract = "The perioperative treatment of muscle-invasive bladder cancer has become a standard procedure in recent years. New agents, such as programmed cell death protein 1 (PD1) and PD1-ligand 1 (PD1-L1) inhibitors have opened up the door for immunomodulation therapy of metastasized bladder cancer. This article focuses on data which have changed or have the potential to change the pharmaceutical treatment of advanced bladder cancer with a review of the literature in Medline PubMed and proceedings of major meetings, e.g. the European Association of Urology (EAU), the American Society of Clinical Oncology (ASCO), the ASCO Genitourinary Cancers Symposium (ASCO GU) and the American Urological Association (AUA).",

keywords = "Bladder cancer, Chemotherapy, adjuvant, Chemotherapy, neoadjuvant, Chemotherapy, palliative, Urothelial cancer",

author = "Schmid, \{S. C.\} and Gschwend, \{J. E.\} and M. Retz",

note = "Publisher Copyright: {\textcopyright} 2014, Springer-Verlag Berlin Heidelberg.",

year = "2014",

month = oct,

day = "8",

doi = "10.1007/s00120-014-3641-y",

language = "Deutsch",

volume = "53",

pages = "1535--1542",

journal = "Urologe - Ausgabe A",

issn = "0340-2592",

publisher = "Springer Medizin",

number = "10",

}

TY - JOUR

T1 - Medikamentöse Therapie des fortgeschrittenen Blasenkarzinoms

T2 - Neue Entwicklungen 2014

AU - Schmid, S. C.

AU - Gschwend, J. E.

AU - Retz, M.

PY - 2014/10/8

Y1 - 2014/10/8

N2 - The perioperative treatment of muscle-invasive bladder cancer has become a standard procedure in recent years. New agents, such as programmed cell death protein 1 (PD1) and PD1-ligand 1 (PD1-L1) inhibitors have opened up the door for immunomodulation therapy of metastasized bladder cancer. This article focuses on data which have changed or have the potential to change the pharmaceutical treatment of advanced bladder cancer with a review of the literature in Medline PubMed and proceedings of major meetings, e.g. the European Association of Urology (EAU), the American Society of Clinical Oncology (ASCO), the ASCO Genitourinary Cancers Symposium (ASCO GU) and the American Urological Association (AUA).

AB - The perioperative treatment of muscle-invasive bladder cancer has become a standard procedure in recent years. New agents, such as programmed cell death protein 1 (PD1) and PD1-ligand 1 (PD1-L1) inhibitors have opened up the door for immunomodulation therapy of metastasized bladder cancer. This article focuses on data which have changed or have the potential to change the pharmaceutical treatment of advanced bladder cancer with a review of the literature in Medline PubMed and proceedings of major meetings, e.g. the European Association of Urology (EAU), the American Society of Clinical Oncology (ASCO), the ASCO Genitourinary Cancers Symposium (ASCO GU) and the American Urological Association (AUA).

KW - Bladder cancer

KW - Chemotherapy, adjuvant

KW - Chemotherapy, neoadjuvant

KW - Chemotherapy, palliative

KW - Urothelial cancer

UR - https://www.scopus.com/pages/publications/84911006548

U2 - 10.1007/s00120-014-3641-y

DO - 10.1007/s00120-014-3641-y

M3 - Artikel

C2 - 25234951

AN - SCOPUS:84911006548

SN - 0340-2592

VL - 53

SP - 1535

EP - 1542

JO - Urologe - Ausgabe A

JF - Urologe - Ausgabe A

IS - 10

ER -

Medikamentöse Therapie des fortgeschrittenen Blasenkarzinoms: Neue Entwicklungen 2014

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this